BAU Journal - Health and Wellbeing
Volume 5 Issue 1
ISSN: 2617-1635

Article 5

October 2022

ANTIPROLIFERATIVE EFFECTS OF SOME MEDICINAL PLANTS ON
COLORECTAL CANCER: A MINI REVIEW
Jamilah Borjac
Associate Professor in Biochemistry, Biological Sciences Department, Faculty of Sciences, Beirut Arab
University, Beirut, Lebanon, j.borjac@bau.edu.lb

Follow this and additional works at: https://digitalcommons.bau.edu.lb/hwbjournal
Part of the Alternative and Complementary Medicine Commons, and the Diseases Commons

Recommended Citation
Borjac, Jamilah (2022) "ANTIPROLIFERATIVE EFFECTS OF SOME MEDICINAL PLANTS ON COLORECTAL
CANCER: A MINI REVIEW," BAU Journal - Health and Wellbeing: Vol. 5: Iss. 1, Article 5.
DOI: https://www.doi.org/10.54729/BSLA1133
Available at: https://digitalcommons.bau.edu.lb/hwbjournal/vol5/iss1/5

This Article is brought to you for free and open access by Digital Commons @ BAU. It has been accepted for
inclusion in BAU Journal - Health and Wellbeing by an authorized editor of Digital Commons @ BAU. For more
information, please contact ibtihal@bau.edu.lb.

ANTIPROLIFERATIVE EFFECTS OF SOME MEDICINAL PLANTS ON COLORECTAL
CANCER: A MINI REVIEW
Abstract
Colorectal cancer (CRC) is one of the highly prevalent and deadly cancers worldwide. Surgery,
chemotherapy and radiotherapy are the conventional treatment modalities for CRC; however, they cause
adverse side effects and can be associated with cancer resistance and relapse. Currently, traditional
herbal medicine is becoming increasingly studied and used in combination with conventional treatments
in CRC. Various medicinal plants have shown promising anticancer effects against CRC concomitant with
negligible side effects. For example, Annona muricata (soursop), Chenopodium quinoa (quinoa), Matricaria
chamomilla (chamomile), and Moringa oleifera (moringa) have shown remarkable antiproliferative effects
against CRC both in vitro and in vivo. Therefore, it is warranted to document the recuperative role of these
potential medicinal plants in CRC. It is also important to provide scientific explanations for these effects
by establishing their effects on key signaling pathways implicated in colorectal carcinogenesis. In this
review, a summary of key signaling pathways that are altered in CRC is presented. The antiproliferative
effects of selected medicinal plants against CRC as well as their underlying mechanisms of action are also
discussed.
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1. INTRODUCTION
Globally, colorectal cancer (CRC) is the third prevalent type of malignancy and the second
cause of cancer-related mortality. In 2020, CRC was newly diagnosed among 1.9 million
individuals and caused 0.9 million fatalities around the world (Xi & Xu, 2021). Based on disease
incidence rates, it is predicted that the worldwide CRC burden will increase by 60% by 2030
(Arnold et al., 2017), and its cases will reach 3.2 million in 2040 (Xi & Xu, 2021). Regarding its
etiology, CRC arises from a complex multi-step process that involves consecutive mutational
events that sequentially drive the transformation of intestinal epithelial cells into malignancy
(Mármol et al., 2017). By far, the most commonly occurring molecular events in CRC involve
genes implicated in key signaling pathways that promote cellular proliferation, invasion and
metastasis (Koveitypour et al., 2019). In fact, studying these pathways have paved the way for
considering them as potential targets for various therapeutic approaches (Farooqi et al., 2019).
In general, CRC is conventionally treated by surgery, radiotherapy, chemotherapy, and
targeted therapy (Ciombor & Goldberg, 2015). Although they show success in treating particular
CRC cases, they are associated with a wide range of adverse events, limited efficacy, disease
relapse and recurrence, and drug resistance (Nurgali, Jagoe, & Abalo, 2018). Meanwhile,
substantial evidence suggests that the use of medicinal plants is associated with efficacy in
preventing and/or treating diverse diseases, including CRC (Benarba & Pandiella, 2018).
Recently, they are being extensively studied due to their minimal toxicity, bioavailability,
affordability, and promising pharmacological activities (Gezici & Şekeroğlu, 2019). In this
context, the current review aims at discussing the major signaling pathways implicated in CRC
as well as highlighting the antiproliferative effect of selected medicinal plant extracts, namely
Annona muricata, Chenopodium quinoa, Matricaria chamomilla, and Moringa oleifera, on CRC
and their underlying mechanisms of action.

2. SIGNALING PATHWAYS IN CRC
Genetic and epigenetic changes lead to the progressive development of CRC (Aghagolzadeh
& Radpour, 2016). In general, the genes involved in sporadic CRC belong to the Wnt, mitogen‐
activated protein kinase (MAPK)/ERK, phosphatidylinositol-3-kinase (PI3K)/Akt, Janus kinase
(JAK)/signal transducer and activator of transcription (STAT), transforming growth factor beta
(TGFβ), nuclear factor kappa B (NF-κB), and TP53 pathways (Kanthan, Senger, & Kanthan,
2012).

2.1. Wnt Pathway
The Wnt signaling pathway is a major cellular pathway that regulates embryonic
morphogenesis as well as adult physiological processes (Yang, 2012). In the absence of Wnt
ligand, β-catenin is sequestered in the destruction complex comprising of adenomatous
polyposis coli protein (APC), scaffold protein Axin, and glycogen synthase kinase (GSK3β).
The kinase in this complex phosphorylates β-catenin, causing its ubiquitinylation and
subsequent degradation in the proteasome. On the other hand, Wnt binding to its frizzled
receptor leads to the dissociation of the destruction complex, thereby causing the
degradation of its components in the cytosol. In turn, β-catenin becomes stabilized in the
cytosol, then it translocates to the nucleus, where it interacts with T-cell factor (Tcf) and
lymphoid enhancer factor 1 (LEF1) to regulate the expression of cell cycle genes, such as cMyc and cyclin D1 (Ding & Ding, 2017). In CRC, the Wnt/β-catenin pathway is aberrantly
activated due to significant mutations in the ctnn1 oncogene that codes for β-catenin and in
the tumor suppressor gene APC. Such mutations render APC incapable of binding β-catenin,
which becomes stabilized in the cytoplasm (Polakis, 2012). Consequently, the signaling
pathway becomes hyperactivated leading to continuous cell division and tumor growth.
Therefore, the effective inhibition of this pathway is a promising way to prevent and treat
CRC (Anastas & Moon, 2013).

Published by Digital Commons @ BAU, 2022

1

BAU Journal - Health and Wellbeing, Vol. 5, Iss. 1 [2022], Art. 5

2.2. MAPK/ERK Pathway
Receptor tyrosine kinases (RTKs) mediate intracellular signal transduction of MAPK
pathways implicated in regulating differentiation, cellular proliferation, and metabolism
(Cargnello & Roux, 2011). The ERK/MAPK pathway is initiated when RTKs become
activated by extracellular stimuli, mainly platelet-derived growth factor (PDGF) and
epidermal growth factor (EGF). Activated RTK binds to the growth factor receptor-bound
protein 2 (Grb2), which in turn activates the protein son of sevenless (sos) (Meister et al.,
2013). Sos facilitates Ras activation through the exchange of GDP by a GTP, and Ras GTP
then activates the kinase protein Raf. Consequently, active Raf phosphorylates MAPK/ ERK
kinase 1 and 2 (MEK1/2) which binds to ERK1/2, activates it, and releases it for target
substrate phosphorylation in the cytosol or the nucleus, where it activates the transcription
of cMyc and cyclin D (Lake et al., 2016). This pathway induces tumorigenesis in 30-50% of
CRC cases (Roberts & Der, 2007). The nuclear translocation following ERK1/2 activation
has been shown to promote CRC cell migration, survival, and invasion (Holck et al., 2016).
Moreover, it regulates the protein and gene expression levels of FOXO3a, a crucial isoform
of the fork head (FOX) transcription factors, which acts as a tumor suppressor in CRC
(Grossi et al., 2019).

2.3. PI3K/Akt Pathway
PI3Ks are lipid kinases that phosphorylate different phosphatidylinositols (Engelman,
Luo, & Cantley, 2006). Akt is a serine/threonine-specific protein kinase that is also known
as protein kinase B (PKB) (Vivanco et al., 2002). The PI3K/Akt pathway is activated once
ligands, such as PDGF or VEGF, bind to their respective tyrosine kinase receptors. This
binding results in the recruitment of class IA PI3K to the cell membrane for the conversion
of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate
(PIP3). The generated PIP3 acts as a second messenger that recruits Akt. Subsequently, Akt
becomes phosphorylated by phosphoinositide dependent kinase 1 (PDK1) and mTORC2,
and it phosphorylates and inactivates the complex of tuberous sclerosis 2 and 1 (TSC2TSC1). This leads to the accumulation of GTP-bound Ras homologue enriched in brain
(RHEB) and activation of mTORC1. Later, mTORC1 phosphorylates p70 S6 kinase and 4Ebinding proteins leading to an increase in protein translation and ribosome biogenesis. The
activation of this pathway leads to a variety of cellular functions, such as cell proliferation
and survival, metabolism, and angiogenesis (Saxton & Sabatini, 2017). In CRC, the
PI3K/Akt pathway is aberrantly activated inducing cell proliferation and cancer cell
survival. In fact, mutations in genes that encode different components of this pathway occur
in ~40% of CRCs (Johnson et al., 2010). Moreover, alterations in the PDGF signaling,
especially in PDGFR-β receptor, have been observed in CRC, where the overexpression of
PDGFRs results in enhanced angiogenesis, invasion, metastasis, and poor survival. Thus,
the use of PDGFs/PDGFRs antagonists combined with therapeutic strategies is being
increasingly used as an approach for cancers therapy (Narayanankutty, 2019).

2.4. JAK/STAT Pathway
The STAT family of proteins comprises seven members that play the same dual roles
as signal transducers across the cytoplasm and as nuclear factors promoting transcription
(Kiu & Nicholson, 2012). STATs were initially identified by their ability to relay signaling
from interferons (IFN) α, β and γ, and IL-6 receptors upon binding to their corresponding
cytokines (Aittomäki & Pesu, 2014). These cytokine receptors are associated with tyrosine
kinases, especially the JAK family of kinases. Commonly, IL-6-mediated pathways lead to
the activation of a JAK that activates the transcription factor STAT3 by phosphorylation
(Bousoik & Aliabadi, 2018). When activated through ligand binding, JAK phosphorylates
diverse tyrosine within the cytoplasmic regions of the receptor generating docking sites for
STAT3. STAT3 is then phosphorylated and translocated to the nucleus to activate gene
transcription (Aittomäki & Pesu, 2014). Particularly, STAT3 activation is well-documented
for modulating a variety of target genes involved in cancer cells’ survival, such as Bcl-2,
Survivin, Myeloid Cell Leukemia 1 (Mcl-1), Bcl-xL, c-Myc, Cyclin D1, VEGF, and IL-6
https://digitalcommons.bau.edu.lb/hwbjournal/vol5/iss1/5
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(Bousoik & Aliabadi, 2018). In CRC, IL-6/JAK/STAT3 is irregularly activated, allowing
cancerous cells escape from the immune system. Moreover, elevated levels of
phosphorylated STAT3 and IL-6 are correlated with tumor progression, invasion,
angiogenesis, and metastasis (Wang et al., 2014).

2.5. TGF Pathway
The tumor growth factor beta (TGFβ) is a multipotent cytokine that regulates cell
growth and differentiation through binding to its TGFβR receptors (Smith et al., 2012). The
TGFβ superfamily comprises different cytokines, including TGFβ, activins, inhibins, bone
morphogenetic proteins (BMPs), and growth differentiation factors (GDFs) (Zhang, 2017).
The TGFβ1 ligand exists as a homo or heterodimer, and it is activated through proteolytic
cleavage. Binding of TGFβ1 to the TGFβRII is facilitated by TGFβRIII. TGFβRI is then
recruited and is phosphorylated by TGFβRII, inducing its kinase activity that phosphorylates
Smad proteins (Xu et al., 2016). These proteins are divided into three classes: receptorregulated Smads (R-Smad), the common mediator Smad (Co-Smad) and the inhibitory
Smads (I-Smad). TGFβRI phosphorylates R-smads (Smad-2, Smad-4), which in turn form
a complex with Smad-4 causing its translocation to the nucleus and its interaction with
various DNA-binding co-activators, co-repressors and transcription factors. These
interactions result in the regulation of different TGFβ responsive genes expression, mainly
p21 and p14 that inhibit cyclin-dependent kinase causing cell cycle arrest in the G1 phase
and suppression of c-Myc and Bcl-2 expression (Zhang, 2017). The TGFβ signaling pathway
plays a paradoxical role in the predisposition and prognosis of CRC. TGFβ is a potent
inhibitor of normal colonic epithelial cells’ transformation by acting as a tumor suppressor
at the early stage of carcinogenesis (Cheruku et al., 2015). On the other hand, it promotes
the survival, invasion and metastasis of CRC cells by acting as a tumor promoter during the
late stage (Calon et al., 2012). Moreover, CRCs harbor somatic mutations in TGFβRII and
SMAD4 members of the TGFβ pathway (Villalba et al., 2017).

2.6. NF-κB Pathway
NF-κB is a key transcription factor that regulates the expression of many genes
involved in inflammation, apoptosis and cell proliferation (Sun, 2012). Different stimuli
activate the NF-κB signaling such as cytokines (TNFα, IL-6 and IL-1β), bacterial
pathogens, viruses, ionizing radiation, and genotoxic agents. These stimuli initiate the
signaling mostly through IκB kinase–dependent (IKK-dependent) phosphorylation and the
ubiquitination and proteasomal degradation of IκB proteins (Sun, 2017). The generated
NF-κB dimers translocate to the nucleus, where they regulate transcription of genes that
encode chemokines, cytokines, growth factors, as well as cell adhesion molecules. The
IKK complex is made up of IKKα and IKKβ subunits, and a non-enzymatic regulatory
component, IKKγ/NEMO (Yu et al., 2020). In CRC, NF-κB promotes cancer progression
through activating cell cycle regulators that make intestine epithelial cells proliferate
rapidly. Also, NF-κB activates inflammatory cells and induces the expression of
chemokines, angiogenic factors, as well as the pro-inflammatory enzymes cyclooxygenase
2 (COX-2) and inducible nitric oxide synthase (iNOS) (Soleimani et al., 2020; Vaiopoulos
et al., 2013). The IKKβ-dependent NF-κB pathway provides a link between inflammation
and CRC (Patel et al., 2018). Therefore, its suppression is associated with limiting the
proliferation of cancer cells making it as an important therapeutic target in CRC (Soleimani
et al., 2020).

2.7.

P53 Pathway
P53 is a gene located on chromosome 17p; it encodes for a tumor suppressor protein
that plays a crucial role in controlling the cell cycle. P53 activation triggers growth arrest
at both cell cycle phases G1 and G2. P53 activation is also involved in interrupting DNA
replication at S phase (Sionov et al., 2013). Moreover, p53 is a pro-apoptotic nuclear
transcription factor and tumor inhibitor. It induces apoptotic cell death by activating
several positive apoptosis regulators, such as Bax. Apoptosis mediated by p53 requires
reactive oxygen species (ROS) generation and mitochondrial depolarization. These events
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permit the release of caspase-9 and Apaf-1 which trigger apoptosis through the activation
of the caspase cascade (Hafner et al., 2019). Besides, p53 regulates energy balance through
activation of the AMPK pathway, cell differentiation, DNA repair, senescence, and
angiogenesis. The activation and accumulation of p53 protein is triggered by a vast array
of stress signals including DNA damage, hypoxia, viral infection, heat shock, and
oncogenic activation (Boutelle & Attardi, 2021). In CRC, the deamination of methylated
cytosine bases causes p53 mutations leading to transition mutations in C/T that are
prevalent in ~60% of CRCs (Li et al., 2015). These mutations drive the transition from
adenoma to adenocarcinoma and are associated with tumor development and
chemoresistance (Hientz, et al., 2017). Gain of function (GOF) mutations in p53 increase
cell proliferation, migration and invasion (Michel et al., 2021).

3. MEDICINAL PLANTS AND CRC
Since the 1900s, scientists have been relying on plant sources to treat various forms of cancer.
Among the anti-cancer drugs approved between 1940 and 2000, more than half of them were
derived from plant-based natural products (Yuan et al., 2016). CRC has been extensively studied
for being treated or prevented by medicinal plants. Despite the fact that it can be manageable by
chemotherapy, this treatment option is associated with numerous side effects, thereby paving the
way for alternative treatments. In this context, medicinal plants may serve as potent
chemopreventive agents because they are rich reservoirs of bioactive molecules that exert
cytotoxic and anti-proliferative effects (Benarba & Pandiella, 2018; Huang et al., 2019).
Substantial evidence proves that extracts of medicinal plants alter distinct signaling pathways
implicated in CRC (Martínez-Aledo et al., 2020). Following is a discussion of the antiproliferative effects of selected medicinal plants of interest with particular emphasis on the
targeted signaling pathways.

3.1. Annona Muricata
3.1.1

Botanical Description
Annona muricata L. (A. muricata), also known as soursop, guanabana, pawpaw, graviola, and sirsak, belongs to the Annonaceae family, order Magnoliales,
division Magnoliophyta, and genus Annona, which includes approximately 70 species
(Coria-Téllez et al., 2018). A. muricata is a tropical plant initially native to South and
North America, but it was later introduced and cultivated in many tropical and
subtropical regions worldwide including India, Malaysia, Nigeria, Cuba, Colombia,
Peru, Madagascar, Cameroon, Togo, Ghana, and New Guinea (Adewole & CaxtonMartins, 2006). A. muricata is a green tree that is 5–10 meter tall with green colored
edible fruit of white and creamy flesh. The fruit has an average weight of 0.4-1 Kg
and may contain up to 170 seeds (Patel & Patel, 2016).

3.1.2

Pharmacological Activities
Extensive studies in the literature reported diverse biological activities of both
aqueous and organic extracts of A. muricata, including anti-cancer, antioxidant,
insecticidal, anti-parasitic, antibacterial, antiviral, and anti-inflammatory activities
(Moghadamtousi et al., 2015; Gajalakshmi et al., 2012; Rady et al., 2018; Bitar et al,
2019). The anti-cancer effects of A. muricata extracts were reported against different
types of cancers both in vitro and in vivo. Treatment with methanolic leaves extract
(200mg/kg) for 5 weeks exerted in vivo cytotoxic effect against breast cancer through
the downregulation of EGFR gene expression (Roham et al., 2016). In addition,
treatment with aqueous leaves extract (30 mg/kg) displayed cytotoxic effect against
breast, pancreatic, prostate, and skin cancers, in vitro and in vivo (Coria-Téllez et al.,
2018; Rady et al., 2018).
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3.1.3

Role in CRC
While the in vitro antiproliferative effects of A. muricata extracts against CRC
were scarcely studied, some studies reported remarkable in vivo effects of this
medicinal plant. In colon cancer cells (COLO-205), treatment with ethyl acetate
leaves extract of A. muricata (10 µg/ml) induced a significant pro-apoptotic effect
(Abdullah et al., 2017). As for the in vivo studies, treatment with ethanoic leaves
extract (300 mg/kg) for 4 weeks reduced ACF formation (Eggadi et al., 2014) and
induced apoptosis in AOM and DMH-induced CRC in rats (Moghadamtousi et al.,
2015; Coria-Téllez et al., 2018).
Several recent studies investigated the potential preventive and therapeutic
efficacy of aqueous A. muricata leaf extract (300 mg/kg; 5 days/week P.O.) on various
signaling pathways involved in 1,2-dimethylhydrazine (DMH)-induced CRC in mice.
In these studies, CRC was induced in mice using 20 mg/kg DMH for 12 and 24 weeks
to study the effects of the prepared plant extract as a pre- and post-treatment. The first
study was carried out by Masri (2021), who determined the effect of this extract on
the Wnt/β-catenin signaling pathway and the levels of inflammatory enzymes COX2 and iNOS. Findings revealed an increase in Wnt, β-catenin, Tcf, Lef, c-Myc, Cyclin
D1 gene expression levels, concomitant with increased COX-2 level and iNOS
activity and a decrease in APC and GSK3β gene expression levels in mice with DMHinduced CRC. Treatment with A. muricata remarkably reversed these effects. Another
study by Itani (2020) aimed at elucidating the effect of the same extract on IL-6activated JAK/STAT3 pathway in the same model of CRC. Results demonstrated an
increase in IL-6 and p-STAT3 levels in DMH-induced CRC tissues compared to the
control group. A. muricata administration significantly reversed these levels when
administered as pre-and post-treatment. Additionally, all target genes of the IL6/JAK/STAT3 signaling pathway (Mcl-1, Bcl-xL and Survivin) which were
upregulated in colorectal tissues of DMH-injected groups, were significantly
minimized upon the administration of A. muricata extract.
Furthermore, Assaf (2020) assessed the effect of this extract on KRASactivated ERK/MAPK pathway and its downstream regulators FOXO3a, c-fos, and
cyclin-D1. Results showed that A. muricata extract, as a pre- and post-treatment,
hindered CRC tumorigenesis represented by a reduction in polyp count. Treatments
significantly decreased KRAS gene expressions and p-ERK1/2 expressions in the
nuclear fraction while they increased that in the cytoplasmic fraction. Also, the extract
significantly decreased oncogenic c-fos and cyclin-D1 gene expression with
insignificant increase in the pro-apoptotic nuclear and cytoplasmic FOXO3a at the
gene and the protein levels. Within the same model, Shmeas (2020) investigated the
effect of A. muricata extract on the PI3K/Akt pathway. Results showed that A.
muricata extract upregulated the expression of pro-apoptotic genes PTEN and p53
while it downregulated that of anti-apoptotic genes VEGF, Girdin and Bcl2. Also, the
extract significantly reduced the level of phospho-Akt. The inhibition of the PI3K/Akt
pathway was more pronounced when the extract was administered as a post-treatment
rather than a pre-treatment. Together, these studies suggest a preventive and
therapeutic role of A. muricata aqueous extract against CRC, through the regulation
of (1) the Wnt signaling pathway, (2) the RAS-activated ERK/MAPK pathway, (3)
the IL-6-activated JAK/STAT3, and (4) the PI3K/Akt pathway as well as some of
their downstream-regulated target genes (Fig. 1). Therefore, A. muricata aqueous
extract may act as both a chemopreventive and a therapeutic natural product against
CRC.
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Fig.1: Effects of A. muricata extract on key signaling pathways involved in DMH-induced
CRC.

3.2. Chenopodium Quinoa
3.2.1

Botanical description
Quinoa (Chenopodium quinoa Willd.) is a herbaceous annual plant that belongs to the
Dicotyledoneae class, Chenopodiaceae family, Chenopodium genus, and quinoa species. It is
about 1–2 meters high with hairy lobed leaves and a woody central stem that may be green,
red or purple in color. The plant has flowering panicles arising from the top and having small
sessile flowers colored same as the sepals. The seeds are ~ 2 mm in diameter of different
colors, such as white, red or black (Maughan et al., 2007). Quinoa was indigenously cultivated
in South America and was regarded as a sacred food, especially in the Lake Titicaca basin
of Peru and Bolivia (Jacobsen, 2003). It can be cultivated at altitudes up 3500 m from sea
level, and it shows tolerance to frost, salinity and drought. Nowadays, its cultivation has spread
to more than 70 countries. Due to its increased popularity and consumption in North America,
Europe, and Australia, the prices of quinoa tripled between 2006 and 2013 (Angeli et al.,
2020).

3.2.2

Pharmacological Activities
Most of the studies on quinoa focus on its seeds’ nutritional aspects,
biodiversity and sustainability while only few address the pharmacological activities
of its extract, especially those from its leaves. One study explored the antioxidant and
immunomodulatory potential of the aqueous and ethanolic quinoa leaf extracts.
Results revealed that ethanolic quinoa extract exerted potent antioxidant and antiinflammatory effects. Also, it had a higher level of total phenolic content and a better
ROS scavenging activity in the lipopolysaccharide (LPS)-induced murine
macrophage RAW.264 compared to the aqueous extract (Chen et al., 2017). More
importantly, phenolic compounds from Chenopodium quinoa leaves extract showed
antiproliferative, antioxidant and antiangiogenic effects on prostate cancer cells
(Gawlik-Dziki et al., 2013).

3.2.3

Role in CRC
Studies on the antiproliferative effect of Chenopodium quinoa leaves aqueous
extract against CRC were done DMH model of CRC. A study by Mahmoud (2021)
investigated the effect of quinoa extract (200 mg/kg, 5 days/week P.O.) on the Wnt
pathway. Polyps count and the histopathological analysis revealed a significant
anticancer effect of this extract when administered as a pre- and post-treatment.
Quinoa extract significantly minimized alterations in Wnt, frizzled receptor (Fzd), β-
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catenin, Tcf, Lef, cyclin D1, APC and GSK3β. It also caused a significant reduction
in the levels of COX-2, iNOS and IL-6. Another study performed by Halawi (2021),
in which the same quinoa extract and CRC model were used, aimed to unravel the
effect of this extract on the PI3K/Akt/mTOR pathway. At the molecular level, the
extract significantly modulated mRNA expression level of PDGF-BB, PDFGR-β and
mTOR genes, which were altered by DMH injections. Moreover, the elevated levels
of phospho-Akt upon DMH administration were reduced by quinoa pre- and posttreatment for 8 weeks. A similar pattern of increased levels of total and
unphosphorylated NF-κB p65 was observed in the studied animals. More importantly,
significant elevations in the level of phospho NF-κB p65 in mice receiving DMH were
reduced upon pre- and 12 weeks post-treatment with quinoa extract. Taken together,
these findings show that quinoa extract has the potential to prevent CRC through
downregulating cell proliferation mediated by the Wnt pathway, reducing
angiogenesis mediated by the PI3K/Akt pathway, and attenuating inflammation
mediated by the NF-κB pathway (Fig. 2).

Fig.2: Effects of C. quinoa extract on some signaling pathways involved in DMH-induced
CRC.

3.3. Matricaria Chamomilla
3.3.1 Botanical Description
Matricaria chamomilla L. (also known as German chamomile) is a valuable
medicinal herb belonging to the daisy family (Asteraceae). It is traditionally used due
to its profound health benefits (Singh et al., 2011). Its flower cones are hollow bright
gold packed with tubular or disc florets ringed with ~ 15 white florets. It is native to
Europe but is now spread in different regions throughout the world (Upadhyay et al.,
2016).

3.3.2 Pharmacological Activities
The in vitro and in vivo pharmacological activities of M. chamomilla have been
considerably studied in the literature (El Joumaa & Borjac, 2022). Several studies
showed that the aqueous extracts of M. chamomilla exert significant antimicrobial
effects against different Gram-positive and Gram-negative bacteria (Al-Ismail & Talal,
2003; Rahman & Chandra, 2015). Also, many research studies referred to the
antioxidant effects of this herb through inhibiting the formation of ROS and enhancing
the activity of antioxidant enzymes in different disease models (Cvetanović et al., 2015;
Published by Digital Commons @ BAU, 2022
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Jabri et al., 2016). Also, M. chamomilla extracts exert hypoglycemic and hypolipidemic
effects in animal models of diabetes mellitus (Hajizadeh-Sharafabad et al., 2020). M.
chamomilla extract exhibits remarkable sedative (Ross, 2013) and hepatoprotective
activities (Aksoy & Sözbilir, 2012). Moreover, the anticancer activity of chamomile
was pre-clinically proven against prostate, breast and ovarian cancer cell lines in vitro
(Srivastava & Gupta, 2007).

3.3.3 Role in CRC
Studies assessing the anti-proliferative effects of M. chamomilla are few. A
study by El Joumaa et al. (2020) aimed at deciphering the chemopreventive and antiproliferative effects of aqueous M. chamomilla extract (150 mg/kg, 5 days/week P.O.)
in DMH model of CRC. The extract suppressed colorectal polyps at the macroscopic
and microscopic levels. At the molecular level, the administration of M. chamomilla
extract as a pre-treatment was more effective that the post–treatment in modulating
the expression levels of gene belonging to the Wnt signaling pathway, such as Wnt,
β-catenin, Tcf, Lef, APC, and GSK3β, as well as its downstream genes c-Myc and
cyclin D1. Using the same model and treatment strategy, Kawach (2018) assessed the
effect of this extract on the TGFβ and NF-κB signaling pathways that are aberrantly
altered in the DMH model of CRC. The extract down-regulated the gene expression
levels of TGFβ, Smad4, and p21 during the early stage of CRC. However, the gene
expression levels of TGFβ and TGFRII were significantly upregulated during the late
stage of carcinogenesis. As for the NF-κB signaling genes, iNOS, COX-2 and NF-κB
were significantly upregulated during early and late stages of CRC. In addition to
being upregulated at the mRNA level, the activity of iNOS and protein level of COX2 were found to be elevated in colonic tissues of mice receiving DMH (El Joumaa et
al., 2020). In contrast, M. chamomilla treatment restored all these altered levels back
to normal. Collectively, these studies showed that M. chamomilla aqueous extract
exhibits anti-proliferative and anti-inflammatory effects against DMH-induced CRC
through modulating the Wnt, TGFβ and NF-κB signaling pathways at early and late
stages of carcinogenesis (Fig. 3).

Fig.3: Effects of M. chamomilla extract on major signaling pathways involved in DMHinduced CRC.
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3.4. Moringa Oleifera
3.4.1

Botanical Description
Moringa oleifera Lam is one of the thirteen best recognized species of
Moringaceae family. The tree belongs to the Plantae kingdom, Magnoliophyta
division, Magnoliopsida class, Brassicales order, Moringaceae family, Moringa
genus, and oleifera species (Abdull Razis et al., 2014). M. oleifera tree is also known
as the horseradish tree, drumstick tree, miracle tree, magic tree, and tree of life. The
plant adapts to a variety of natural conditions, in which it thrives in dry to humid
climates with annual rainfall ranging from 25-300 cm and temperatures between 1928°C. M. oleifera is cultivated in different areas worldwide, including the western and
sub-Himalayan tracts, India, Pakistan and Africa (Raja et al., 2016).

3.4.2

Pharmacological Activities
Extracts prepared from different parts of the M. oleifera tree have shown
diverse pharmacological activities. M. oleifera leaves possess antioxidant properties
against chemically-induced oxidative stress in mice (Verma et al., 2009). They also
possess remarkable anti-inflammatory effects as they reduce the production of the
cytokines TNF-α, IL-6 and IL-8 (Martínez-González et al., 2017). In addition, M.
oleifera leaves extract exerts hepatoprotective effects against liver damage in mice
(El-bakry et al., 2016). M. oleifera leaves extracts were shown to exhibit
cardioprotective (Nandave, M., et al., 2009), nephroprotective (Akinrinde et al.,
2020), hypolipidemic, and hypoglycemic effects (Chen et al., 2020) in vivo.
Extensive research has focused on the anticancer effects of M. oleifera leaves’
extracts (Charoensin, 2014). Sreelatha et al. (2011) revealed that M. oleifera leaves
extract inhibits the proliferation of human epithelial carcinoma cells (KB cell line).
Other studies also confirmed the antiproliferative effects of M. oleifera leaves extracts
on pancreatic cancer (Berkovich et al., 2013) and leukemia (Khalafalla et al., 2010)
by downregulating the NF-κB signaling and inducing apoptosis, respectively.
Moreover, Madi et al. (2016) reported the apoptotic effect of M. oleifera crude water
extract on A549 lung cancer cells by inhibiting proliferation and increasing p53 and
AIF levels as well as ROS production. Al-Asmari et al. (2015) reported that leaves
extract of M. oleifera displayed antiproliferative eﬀects in colon (HCT-8) and breast
(MDA-MB-231) cancer cell lines. Similar findings were reported by Gaffar et al.
(2019) in T47D breast cancer cell line.

3.4.3

Role in CRC
Reda et al. (2017) investigated the anti-cancer effect of 0.1-2.5% M. oleifera
aqueous leaves extract (MOE) on different colorectal cancer cell lines, namely
HCT116, CACO2, and HCT116P53-/-. Results showed that MOE induced a dose and
time-dependent decrease in viability (IC50 0.02-0.05%) and increase in ROS
production. The extract also disrupted membrane integrity of cancer cells as evident
by the release of lactate dehydrogenase upon MOE treatment. Another study that was
also carried out by Reda et al. (2020) unraveled the mechanism of action of MOE
extract. It showed that MOE induces the dissipation of mitochondrial membrane
potential by increasing the intracellular oxidative stress, thereby causing a decrease in
ATP level. In addition, an increase in preG0 and late apoptotic events were observed.
In particular, the antiapoptotic effect of MOE extract was further corroborated by its
ability to significantly modulating the altered expression levels of Bax, p53 and AIF
in the studied CRC cell lines.
Similarly, studies by Pamok et al. (2012) reported a dose-dependent anticancer
effect of aqueous and ethanol extracts (0.1-1 mg/ml) against HCT15, SW48 and
SW480 CRC cell lines. Moreover, Al-Asmari and colleagues (2015) and
Tragulpakseerojn et al. (2017) showed that M. oleifera aqueous extracts exert
apoptotic effects against HCT-8 and HCT116 CRC cell lines. Several studies by
Cuellar-Núñez et al. (2018, 2020, 2021) further showed that M. oleifera leaves
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suppress CRC both in vitro and in vivo through mitigating inflammation and oxidative
stress. In sum, these studies suggest that M. oleifera leaves extract possesses an anticancerous therapeutic potential against CRC (Fig. 4).

Fig.4: Effects of M. oleifera extract on major signaling pathways involved in CRC.

4. CONCLUSION
CRC is a prevalent disease that can be prevented and treated by some medicinal plants.
Such plants possess potent antiproliferative effects, which are attributed to their richness in
bioactive compounds. The presented medicinal plants herein, namely A. muricata, C. quinoa, M.
chamomilla, and M. oleifera, have potent antiproliferative effects against CRC, suggesting their
consideration as natural therapeutic choices for the treatment and chemoprevention of CRC. The
present review suggests that these plants can be used in combination with chemotherapeutic drugs
to minimize their side effects.
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